Viridian selects VRDN-003 as lead SC program for TED; half-life 40-50 days, pivotal mid-2024

Viridian Therapeutics, Inc.\DE

VRDN-003 showed extended half-life of 40-50 days, 4–5× longer than VRDN-001.
No serious adverse events; all treatment-related AEs were grade 1 (mild) and no antidrug antibodies detected.
Modeled dosing supports once-every-8-weeks (Q8W) schedule; Q4W and Q2W also predicted to achieve robust exposure.
VRDN-001 SC and VRDN-002 SC development deprioritized in favor of VRDN-003.
Global pivotal trials expected to begin mid-2024 pending regulatory alignment.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Viridian Therapeutics, Inc.\DE: Amended bylaws to designate federal district courts as sole and exclusive forum for Securities Act claims (effective 2023-12-15).

Change: bylaw amendment
Effective: 2023-12-15

Exact text from the filing

Effective December 15, 2023, the board of directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) adopted the Fourth Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws have been amended to designate the federal district courts of the United States as the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the “Securities Act”).

View on SEC.gov

71 governance changes filed in the last 30 days. Browse all governance changes →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-297131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.